BioCentury | Jun 26, 2020
Distillery Therapeutics

CDK12 identified as myotonic dystrophy target

DISEASE CATEGORY: Musculoskeletal INDICATION: Myotonic dystrophy type 1 (DM1) Inhibiting the transcription elongation regulator CDK12 could treat DM1, which is caused by CTG repeat expansions in the DMPK gene that result in cellular accumulation of...
BioCentury | Jun 23, 2020
Distillery Therapeutics

CDKL5 identified as target in acute kidney injury

DISEASE CATEGORY: Renal INDICATION: Renal damage Inhibiting the kinase CDKL5 could treat acute kidney injury (AKI). In kinome-wide siRNA screens in human and mouse renal tubular epithelial cells, CDKL5 was the gene for which knockdown...
BioCentury | Jun 17, 2020
Product Development

Data in early breast cancer recurrence point to larger market for Lilly’s Verzenio

The positive Phase III readout of Lilly’s Verzenio in early breast cancer opens a path to a new market for the CDK4 and CDK6 inhibitor, one that was recently made clearer by the failure of...
BioCentury | Jun 1, 2020
Product Development

Ibrance failure in adjuvant breast cancer opens door for Novartis, Lilly

The failure of Pfizer’s second-best-selling drug Ibrance in a pivotal trial as an adjuvant treatment for breast cancer opens a window for rival drugs in an indication that could have been a major growth opportunity...
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Inhibiting AFF4 and CDK9, components of the transcription-regulating super elongation complex, could treat diffuse midline glioma. In human diffuse midline glioma cell lines, shRNAs targeting AFF4 or CDK9 or...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | Apr 14, 2020
Deals

Expanded deal with Kyowa could give MEI cash through drug approval

Building on a 2018 deal in Japan, MEI Pharma granted Kyowa Kirin ex-U.S. rights to its PI3Kδ inhibitor ME-401 in an expanded partnership that could shore up the San Diego-based biotech’s balance sheet through a...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | Feb 1, 2020
Distillery Therapeutics

CDK7 inhibition for treating small cell lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting CDK7, a cell cycle regulator, could treat small cell lung cancer (SCLC) and enhance the efficacy of checkpoint inhibition and chemotherapy. In mouse and human SCLC cell lines,...
BC Extra | Jan 28, 2020
Company News

Bourla chooses BD over buybacks in 2020

CEO Albert Bourla outlined his vision for the new innovative business that will emerge from Pfizer after the spin-off of Upjohn, saying that the company would invest in business development and pipeline growth rather than...
Items per page:
1 - 10 of 558